Jupiter Neurosciences, Inc. (JUNS) stock
JUNSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.52−0.18 (-10.59%)
Close on Nov 17, 2026Market cap $1.17MP/E –Yield –
Jupiter Neurosciences r&d expenses
Research and development expenses are spending on new products and technology.
Jupiter Neurosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.87M, up 23.2% year over year. For fiscal 2025 it was $2.09M, up 323.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.09M | +323.5% |
| FY2024 | Dec 31, 2024 | $492.66K | -48.4% |
| FY2023 | Dec 31, 2023 | $954.79K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $600.35K | -20.9% |
| Q1 FY2026 | Mar 31, 2026 | $411.05K | -11.9% |
| Q4 FY2025 | Dec 31, 2025 | $43.68K | -78.3% |
| Q3 FY2025 | Sep 30, 2025 | $816.70K | +788.6% |
| Q2 FY2025 | Jun 30, 2025 | $759.45K | +651.4% |
| Q1 FY2025 | Mar 31, 2025 | $466.75K | +373.1% |
| Q4 FY2024 | Dec 31, 2024 | $201.01K | -17.9% |
| Q3 FY2024 | Sep 30, 2024 | $91.91K | -61.6% |
| Q2 FY2024 | Jun 30, 2024 | $101.08K | – |
| Q1 FY2024 | Mar 31, 2024 | $98.67K | – |
| Q4 FY2023 | Dec 31, 2023 | $244.73K | – |
| Q3 FY2023 | Sep 30, 2023 | $239.46K | – |
See a number that looks wrong?